U. Matulonis

724 total citations
33 papers, 596 citations indexed

About

U. Matulonis is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, U. Matulonis has authored 33 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Reproductive Medicine and 8 papers in Molecular Biology. Recurrent topics in U. Matulonis's work include Ovarian cancer diagnosis and treatment (14 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). U. Matulonis is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). U. Matulonis collaborates with scholars based in United States, Germany and Italy. U. Matulonis's co-authors include Christine Lamont, JD Griffin, Chrysoula Dosiou, LM Nadler, GJ Freeman, P Mauch, Michael V. Seiden, David C. Harmon, Geraldine Goss and José Jimeno and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

U. Matulonis

31 papers receiving 581 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
U. Matulonis United States	9	342	252	126	125	122	33	596
Ewa Chmielowska Poland	12	251 0.7×	132 0.5×	46 0.4×	109 0.9×	70 0.6×	44	468
M.R. Sertoli Italy	15	432 1.3×	75 0.3×	73 0.6×	120 1.0×	136 1.1×	34	630
Nicole Kelbick United States	7	260 0.8×	94 0.4×	63 0.5×	158 1.3×	75 0.6×	9	522
Volker Moebus Germany	15	393 1.1×	97 0.4×	51 0.4×	164 1.3×	144 1.2×	52	705
Taren Johnston United States	7	120 0.4×	118 0.5×	35 0.3×	264 2.1×	199 1.6×	9	638
J. Cheng United States	12	331 1.0×	148 0.6×	88 0.7×	150 1.2×	41 0.3×	27	504
M. R. Sertoli Italy	11	391 1.1×	67 0.3×	185 1.5×	141 1.1×	87 0.7×	26	638
Anna Maria Mosconi Italy	13	364 1.1×	90 0.4×	20 0.2×	140 1.1×	136 1.1×	39	558
Zaid Abdel Rahman United States	9	350 1.0×	82 0.3×	126 1.0×	67 0.5×	25 0.2×	38	570
Ian Mak United Kingdom	9	147 0.4×	137 0.5×	179 1.4×	230 1.8×	154 1.3×	11	591

Countries citing papers authored by U. Matulonis

Since Specialization

Citations

This map shows the geographic impact of U. Matulonis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Matulonis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Matulonis more than expected).

Fields of papers citing papers by U. Matulonis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Matulonis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Matulonis. The network helps show where U. Matulonis may publish in the future.

Co-authorship network of co-authors of U. Matulonis

This figure shows the co-authorship network connecting the top 25 collaborators of U. Matulonis. A scholar is included among the top collaborators of U. Matulonis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Matulonis. U. Matulonis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2023). 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Annals of Oncology. 34. S467–S467. 1 indexed citations

Oaknin, Ana, Sandro Pignata, Hannelore Denys, et al.. (2022). 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer. Annals of Oncology. 33. S822–S823. 5 indexed citations

Matulonis, U., Katherine Moore, Domenica Lorusso, et al.. (2022). 592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer. Annals of Oncology. 33. S817–S817. 2 indexed citations

Wright, Alexi A., et al.. (2020). Stepping into survivorship: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecologic Oncology. 159. 322–322. 1 indexed citations

Arend, Rebecca C., Cesar M. Castro, U. Matulonis, et al.. (2019). Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies. Gynecologic Oncology. 154. 34–34. 4 indexed citations

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2019). Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours. Annals of Oncology. 30. v164–v164. 16 indexed citations

Lord, Rosemary, Mansoor Raza Mirza, Linn Woelber, et al.. (2018). Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology. 149. 11–11. 2 indexed citations

Bruner, Deborah Watkins, Jennifer Moughan, Bradley R. Prestidge, et al.. (2018). Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 102(3). S2–S3. 11 indexed citations

Matulonis, U., Lewis C. Cantley, C. Whalen, et al.. (2013). Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC). Cancer Research. 73(24_Supplement). OT1–4.

10.

Frangos, John A., et al.. (2012). Carcinoma Erysipeloides of the Breast in a Patient With Advanced Ovarian Carcinoma. Clinical Infectious Diseases. 54(4). 575–576. 1 indexed citations

11.

Viswanathan, Anand, et al.. (2011). The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers.. Journal of Clinical Oncology. 29(15_suppl). 5101–5101. 1 indexed citations

12.

Ledermann, Jonathan A., Philipp Harter, Michael Friedländer, et al.. (2011). Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. Journal of Clinical Oncology. 29(15_suppl). 5003–5003. 48 indexed citations

13.

Wright, A. A., Matthew Nilsson, Maria Roche, et al.. (2010). Associations between age and quality of life in advanced ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). 5085–5085. 1 indexed citations

14.

Hirte, Hal W., W. P. McGuire, Robert P. Edwards, et al.. (2010). Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). 5002–5002. 4 indexed citations

15.

Hirte, Hal W., W. P. McGuire, Robert P. Edwards, et al.. (2009). A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 27(15_suppl). 5559–5559. 4 indexed citations

16.

Kornblith, Alice B., et al.. (2008). Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. Journal of Clinical Oncology. 26(15_suppl). 5590–5590. 1 indexed citations

17.

Makhija, Sharmila, F. Ueland, Don S. Dizon, et al.. (2007). Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology. 25(18_suppl). 5507–5507. 19 indexed citations

18.

Cannistra, S A, U. Matulonis, Richard T. Penson, et al.. (2006). Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clinical Oncology. 24(18_suppl). 5006–5006. 43 indexed citations

19.

Seiden, Michael V., H. A. Burris, U. Matulonis, et al.. (2005). A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Journal of Clinical Oncology. 23(16_suppl). 3151–3151. 8 indexed citations

20.

García‐Carbonero, Rocio, Judith Manola, Michael V. Seiden, et al.. (2004). Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology. 22(8). 1480–1490. 250 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact